Precision NanoSystems to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

Press Release

April 25, 2019

Vancouver, British Columbia– Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines used in oncology, rare disease and infectious disease, today announced that Dr. James Taylor, PNI’s Chief Executive Officer and Co-founder, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, Canada on Wednesday, May 1, 2019 at 11:00 am ET. 

“We are excited about our strong commercial momentum and continued rapid adoption of PNI’s platform,” said Dr. James Taylor, PNI’s Chief Executive Officer and Co-founder, “In 2019, we look forward to launches of innovative product and continuing to work with our clients to develop transformative medicines.“

About Precision NanoSystems Inc.

Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.

About the Bloom Burton & Co. Healthcare Investor Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.


IN THE NEWS

Press Release

Precision NanoSystems (PNI) is excited to be participating in this year’s SfN conference, Nov. 15th to 19th in Washington, DC. The Walter E. Washington Convention Center will play host to over 30,000 d...

Read More


News Article

Precision NanoSystems NanoAssemblr™ platform has been selected for the controlled manufacture of nanomedicines as part of the multinational B-SMART (Brain-Specific, Modular and Active RNA Therapeutics) translational research project… Read More



MENU